Nanobac Pharmaceuticals, Inc. - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for Nanobac Pharmaceuticals, Inc.. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

Nanobac Pharmaceuticals, Inc.. The Group's principal activity is the research and development of therapeutic and diagnostic technologies relating to the pleomorphic pathogen known as nanobacterium sanguineum. The Group is biolifescience company which develops diagnostic tests for the detection of Nanobacterial infection, as well as medications that treat atherosclerosis and coronary heart disease. It has a commercially available serology test for the identification of nanobacterial antibodies and antigens. It also conducts biomedical research and clinical studies in the development of atherosclerosis, gall stones, chronic prostatitis, diabetes, arthritic spurs, cataracts, scleroderma, kidney cysts and kidney stones, certain breast pathology, polycystic kidney disease, solid tumor pathologies, immunosuppressed conditions, dental pulp stone, and neurodegenerative disease. It majorly operates in the United States and Finland.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report